Oxford BioDynamics Plc (LON:OBD) CSO Dr Alexandre Akoulitchev explains to DirectorsTalk how and why its aligned itself with the ALS field, how its biomarker work will help with more successes in therapeutic developments for ALS and how useful it is to other actionable patient stratifications in neurodegerative and neuropsychiatric conditions.
Oxford BioDynamics Plc is a biotechnology company focused on the discovery and development of epigenetic biomarkers for use within the pharmaceutical and biotechnology industry. The Company’s award-winning, proprietary technology platform, EpiSwitch™, aims to accelerate the drug discovery and development process, improve the success rate of therapeutic product development and take advantage of the increasing importance of personalised medicine.
In particular, EpiSwitch™ can reduce time to market, failure rates and the costs at every stage of drug discovery. Additionally, the technology provides significant insights into disease mechanisms for drug discovery and product re‐positioning programmes, and enables the personalisation of therapeutics for patients in the context of challenging pricing environments where improved clinical outcomes are critical.
